Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Cash And Cash Equivalents At Carrying Value of $29.0 thousand for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -84.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2000 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $29.0 thousand | Fiscal year 2024: $187.0 thousand | Fiscal year 2023: $1.30 million | Fiscal year 2022: $772.0 thousand | Fiscal year 2021: $18.86 million | Fiscal year 2020: $37.83 million | Fiscal year 2019: $536.0 thousand | Fiscal year 2018: $942.0 thousand | Fiscal year 2017: $2.48 million | Fiscal year 2016: $547.0 thousand | Fiscal year 2015: $428.0 thousand | Fiscal year 2014: $4.25 million | Fiscal year 2013: $3.50 million | Fiscal year 2012: $1.32 million | Fiscal year 2012: $843.0 thousand | Fiscal year 2011: $1.92 million | Fiscal year 2011: $2.90 million | Fiscal year 2011: $3.66 million | Fiscal year 2010: $93.0 thousand | Fiscal year 2010: $749.0 thousand | Fiscal year 2009: $1.0 thousand | Fiscal year 2000: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: